港股上市公司荣昌生物（09995.HK）今日盘中大涨5.01%，引起市场关注。这一涨幅出现在公司宣布配股计划之后，显示投资者对公司未来发展前景持乐观态度。
根据公司公告，荣昌生物计划以每股42.44港元的价格配售1900万股新H股，较5月21日收盘价46.9港元折让约9.51%。此次配股将为公司筹集约7.96亿港元净额。公司表示，募集资金将用于投资核心产品泰它西普（RC18）的核心适应症拓展，如重症肌无力、膜性肾病等，以及其他一般企业用途。
尽管配股价格有所折让，但投资者似乎对公司的融资计划及未来发展持积极态度。这反映在今日的股价表现上，从早盘的下跌转为显著上涨。分析人士认为，这可能是因为市场看好公司加大对核心产品的投入，预期这将有助于提升公司的长期竞争力和盈利能力。荣昌生物此次融资动作，或将为其在生物制药领域的进一步发展奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.